The U.S. Department of Defense has released detailed instructions regarding a new mandatory policy for screening testosterone deficiency in active-duty and reserve service members aged 30 and above. This policy follows an announcement made in July by U.S. Secretary of Defense Pete Hegseth.
Effective immediately, the guidance sets forth standardized screening and treatment protocols for both male and female service members with the aim of enhancing military readiness by addressing hormonal and energy-related issues.
Hegseth, a proponent of testosterone use, introduced this requirement last month, prompting discussions among experts about the scientific rationale behind such a directive. The U.S. Food and Drug Administration is scheduled to convene a panel of experts in mid-September to explore the medical application of testosterone.
Under the new guidelines, men aged 30 and older will undergo compulsory testosterone blood tests, while younger men will only be tested upon request or if healthcare providers observe concerning symptoms.
Regarding women, routine testosterone blood tests are not mandated, but screening for fatigue and menstrual irregularities associated with hormonal imbalances and conditions like low-energy availability and relative energy deficiency in sport is recommended.
The guidelines outline criteria for prescribing off-label testosterone to women, particularly postmenopausal women experiencing significantly reduced sexual desire.
Some medical professionals have expressed reservations about widespread testosterone testing, citing concerns about unnecessary or potentially harmful treatments. They argue that there is limited evidence to suggest that universal screening for low testosterone in military personnel would enhance U.S. combat readiness.